Screening Platform for Clinical Trials in Advanced Colorectal Cancer (SPECTAcolor)

European Organisation for Research and Treatment of Cancer (EORTC)

Status: Completed

Conditions: Advanced Colorectal Cancer; Colorectal Cancer

Treatments: Genetic: Tumour markers testing

Study type: Observational

Funder types: NETWORK

Identifiers

NCT01723969

2012-003714-14 (EudraCT Number)

EORTC-40CRC

Details and patient eligibility

About

The EORTC GastroIntestinal Tract Cancer Group and the EORTC HeadQuarters wish to set up a European screening platform for advanced colo-rectal cancer (CRC) patients. The goal of this screening platform is to provide quick access to new drugs to patients by offering a new structure for clinical trials.

Currently some of the most challenging clinical questions arise from the molecular sub-division of CRC that would theoretically allow to inhibit the specific, altered pathways in the patients.

A major problem for trials in this "personalized medicine" is that the low frequency of the different mutations requires a high effort for screening and identifying the patients.

The EORTC CRC screening platform will hopefully offer a feasible and efficient way to characterize the patients on the molecular basis of their tumors and allow to offer them rapid and preferential participation in clinical studies with new drugs targeted to their specific pathway alterations.

Enrollment: 668 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Colo-rectal cancer (advanced or metastatic)
• Before patient registration, written informed consent must be given according to ICH/GCP, and national/local regulations.

Exclusion criteria

• Absence of patient's consent

Trial design

668 participants in 1 patient group

Colo-rectal cancer

Description:

Tumour markers testing in patients with advanced or metastatic colo-rectal cancer

Treatment:

Genetic: Tumour markers testing